Introduction {#S0001}
============

Glioma (GM), the most commonly found tumor in the brain, has shown an increasing trend in its incidence and mortality rate, making it a deadly malignancy worldwide.[@CIT0001],[@CIT0002] Although improved diagnostic and therapeutic approaches have improved patient survival, the prognosis continues to remain poor.[@CIT0003] Currently, the biomarkers for prognosis of GM are mainly based on the clinical and pathological stage of the tumor.[@CIT0003] However, significantly different progression and outcomes could be observed in patients that presented with same clinical symptoms and were treated with similar therapeutic regimens. Therefore, novel prognostic factors need to be identified on priority basis for the GM patients.

Circular RNAs (circRNAs) are a class of non-coding RNA molecules with closed circular structures and lack the ability to encode proteins.[@CIT0004],[@CIT0005] These RNAs take an important effect in generation, proliferation and metastasis of tumor cells by modulating the oncogenic and tumor suppressor pathways.[@CIT0006] Further, numerous studies have shown that the abnormal regulation of circRNAs in a variety of tumors may affect cell proliferation and apoptosis, together with their role in tumorigenesis and drug resistance.[@CIT0007]--[@CIT0010] As a tumorigenic circRNA, circ_0030235 was found to be overexpressed in pancreatic ductal adenocarcinoma and promoted cell proliferation and metastasis by targeting miR-1253 and miR-1294.[@CIT0011] In breast cancer, hsa_circ_0004771 contributed to cell oncogenesis by modulating the miR-653/ZEB2 signaling pathway.[@CIT0012] However, the expression, mechanism, and clinical significance of circRNAs in GM remain to be fully investigated.

Wang screening high-throughput sequencing of circRNA on GM specimens and their corresponding non-cancer tissues, and found circ_0079586 to be up-regulated in the GM tissues.[@CIT0013] Circ_0079586 is located at chr7: 23353140--23383472 and is generated by splicing of *IGF2BP3*. This circRNA is 586 base pairs (bp) in length. Here, our analysis has identified the circ_0079586/miR-183-5p/*MDM4* axis has a certain impact on cell growth, apoptosis, migration and metastasis in GM, and may serve as a newer biomarker for prognosis of the patients.

Materials and Methods {#S0002}
=====================

Ethics Statement {#S0002-S2001}
----------------

According to the ethical principle, which is proclaimed in the Declaration of Helsinki, ethical approval was acquired under the discussion debated by the ethical board of the Fourth Affiliated Hospital of Harbin Medical University (ethical approval code 2020-CILLSC-02).

Experimental Specimens and Cell Culture {#S0002-S2002}
---------------------------------------

Tissue samples were acquired from all the patients with informed consent and approval for the study was obtained from the Ethics Committee of the Affiliated Hospital of Harbin Medical University. A total of sixty paired fresh tumor and corresponding noncancerous tissue specimens were obtained and stored at −80°C.

Human GM cell lines (U87MG, U251, U118 and LN229H4) and NHA cells were purchased from the Chinese Academy of Sciences (Shanghai). All the cell lines were cultured in DMEM/RPMI-1640 containing 10% FBS at 37°C and in an atmosphere containing 5% CO~2~.

qRT-PCR {#S0002-S2003}
-------

Total RNA was extracted using TRIzol reagent (Invitrogen). MicroRNA levels were detected using the TaqMan MicroRNA Assay. GAPDH and *U6* small nuclear *RNA* (U6 *snRNA*) were used as the reference RNAs. Relative RNA expression was measured using the SYBR Green System. The 2^−ΔΔCt^ method was used to determine the relative RNA levels.

Cell Transfection {#S0002-S2004}
-----------------

The miR-183-5p mimics and inhibitor, siRNAs targeting circ_0079586 and MDM4, and the negative controls for each were purchased from Genepharma (Shanghai, China). The *pcDNA-3.1-circ_0079586 mini vector* and *pcDNA.3.1-MDM4* were purchased from the GeneSeed (Guangzhou, China). Transfection assays were performed using Lipofectamine 3000 (Invitrogen, USA) as per the directions of the manufacturer.

Cell Counting Kit-8 (CCK-8) {#S0002-S2005}
---------------------------

CCK-8 assay (Bimake, Houston, USA) was performed to assess the effect of circ_0079586 on LN229 and U251 cells growth. 2×10^3^ cells/well were plated into 96-well plates. Absorbance was measured at 450 nm using a microplate every 24 hours to assess cell proliferation after addition of 10 μL of the CCK-8 reagent and incubated at 37°C.

Cell Apoptosis Assay {#S0002-S2006}
--------------------

Apoptosis assay was used Annexin V-FITC and propidium iodide (PI; BD Biosciences, USA) for double staining. Briefly, collect and resuspend the cells in Binding Buffer, add AnnexinV-FITC and PI, incubate for 10 minutes in the dark at room temperature, and then subjected to flow cytometric analysis.

Wound Scratch Test {#S0002-S2007}
------------------

Each well was overspread with 5 x 105 cells. Scratch the vertical line of the monolayer cells with a 200μL pipette tip. After capturing images at 0h and 36h, the images were processed using the Image J software.

Transwell Assay {#S0002-S2008}
---------------

In the cell migration and invasion test, LN229 and U251 cells were placed in 24-well transwell chambers, and cell migration assays were performed using pre-coated Matrigel, and cell invasion assay was performed without Matrigel. Fill the lower compartment with complete medium. After 24h of culture, non-migrating/invasive cells were removed with a cotton swab, and the migrating/invasive cells were fixed with methanol and then stained with crystal violet. Count and capture images of stained cells in each well.

Western Blotting Assay {#S0002-S2009}
----------------------

Proteins were isolated by RIPA buffer, quantified, 30µg protein was added to each lane of SDS-PAGE gel for electrophoretic separation, and the protein was transferred onto PVDF membrane. The membranes were blocked and then exposed to antibodies against GAPDH or MDM4 (Abcam, Cambridge, MA, USA). Further, the blots were incubated with the secondary antibody (Zhongshanjinqiao, China). RapidStep ECL Reagent (Millipore, Billerica, MA, USA) was used to analyze the intensity of each protein band.

Subcellular Fractionation {#S0002-S2010}
-------------------------

Cytoplasmic and nuclear RNAs were isolated with the PARIS Kit (Life Technologies, USA) and quantified by qRT-PCR with the internal references of *GAPDH* and *U6*, respectively.

Luciferase Reporter Assay {#S0002-S2011}
-------------------------

To detect whether miR-183-5p could bind the 3ʹ-UTR of *MDM4*, we cloned the 3ʹ-UTR amplification product of *MDM4* downstream of the firefly luciferase gene in the pGL3 vector (Promega). We named the vector as wild-type (WT). GeneTailor Site-Directed Mutagenesis System (Invitrogen, USA) was used to perform site-directed mutagenesis of the miR-183-5p binding sites in the 3ʹUTR of *MDM4*. We named this vector as mutant (MUT). Cells were co-transfected with the vector and the miR-183-5p mimics or negative control. Similarly, the mutant seed or wild-type region of circ_0079586 carrying the putative target site for the miR-183-5p was cloned into the pGL3 vector. Cells were co-transfected with the MUT or WT circ_0079586 vector and the miR-183-5p mimic or negative control. Thirty-six hours post-transfection, the Dual-Luciferase Reporter Assay System (Promega) was used to assess the extent of interaction in each set.

Data Analysis {#S0002-S2012}
-------------

Data were analyzed using the SPSS software, version 20.0 (Chicago, IL, USA). Two-tailed *t*-test of one-way ANOVA was used to compare groups. Spearman correlation was used to determine the correlation between the expression of circ_0079586 and miR-183-5p/*MDM4*. The clinical significance of circ_0079586 was evaluated by the Fisher's exact test, Kaplan--Meier survival curve, and Cox regression analysis. *P* \< 0.05 represents statistically significant values.

Results {#S0003}
=======

Circ_0079586 Is Overexpressed in GM Tissues and Cells and Associates with Unfavorable Prognosis {#S0003-S2001}
-----------------------------------------------------------------------------------------------

First, total tissue RNA was isolated from clinical GM specimens and matched normal brain samples (N = 60). The qRT-PCR analysis identified an increased expression of circ_0079586 in GM than in normal brain tissues ([Figure 1A](#F0001){ref-type="fig"}). Additionally, it was found to be up-regulated in the GM cell lines than in the NHA cells ([Figure 1B](#F0001){ref-type="fig"}). And then, we explored the clinical significance of the expression of circ_0079586 and separated the patients into two groups on the basis of the median value of circ_0079586, namely the high expression group or the low expression group. We also examined the correlation between the patient's clinical features and circ_0079586 expression. Our analysis suggested that the circ_0079586 expression was significantly elevated in the GM samples (WHO tumor grade III and IV) than in the WHO tumor grade I and II samples (*P* = 0.001). While the expression of circ_0079586 correlated with tumor size (*P* = 0.037), it did not correlate with factors such as age, gender, and tumor location (*P* \> 0.05) ([Table 1](#T0001){ref-type="table"}). Interestingly, high expression of circ_0079586 correlated with poor overall survival in GM patients ([Figure 1C](#F0001){ref-type="fig"}). Furthermore, while the univariate analysis indicated WHO grade (*P* = 0.032) and circ_0079586 expression (*P* = 0.010) as prognostic indicators for GM patients, the multivariate analysis failed to demonstrate the prognostic role of circ_0079586 (*P* \> 0.05) ([Table 2](#T0002){ref-type="table"}). Taken together, our analysis indicates that the circ_0079586 is over-expressed in GM, and correlates with tumor size and poor survival outcome.Table 1Correlation Between circ_0079586 Expression and Clinicopathological Parameters of Glioma PatientsClinicopathological FeaturesNo. of Patientscirc_0079586 Expression*p*-valueHighLowGender0.601 Male351916 Female251114Age0.143 \<45441925 ≥4516115Family history of cancer0.333 Yes1248 No482622Tumor location0.589 Supratentorial392118 Infratentorial21912Tumor size0.037\* \<3cm27918 ≥3cm332112WHO grade0.001\*\* I--II25619 III--IV352411[^1] Table 2Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival in Glioma PatientsVariablesUnivariate AnalysisMultivariate AnalysisHR95% CI*p-*valueHR95% CI*p-*valueOverall SurvivalGender\
(Male vs Female)0.8140.450--1.4720.496Age\
(≥45 vs \<45)0.9600.495--1.8620.904Family history of cancer\
(Yes vs No)0.9500.457--1.9740.891Tumor location\
(Supratentorial vs infratentorial)1.0820.582--2.0120.804Tumor size\
(≥3cm vs \<3cm)1.8190.998--3.3150.051WHO grade\
(III--IV vs I--II)1.9781.060--3.6910.032\*1.4590.713--2.9850.301circ_0079586 expression\
(High vs Low)2.2231.212--4.0790.010\*1.8450.920--3.7000.085[^2] Figure 1Relative expression of circ_0079586 in GM tissues and cell lines and its clinical significance. (**A**) Relative expression of circ_0079586 in GM samples and paired non-cancerous samples measured by qRT-PCR. (**B**) Relative expression of circ_0079586 in GM and normal cell lines measured by qRT-PCR. (**C**) Kaplan--Meier survival analysis showing correlation between circ_0079586 expression and overall survival in GM patients. \*\**p* \< 0.01.

Circ_0079586 Contributes to Progression in GM Cells {#S0003-S2002}
---------------------------------------------------

For the highest expression of circ_0079586, LN229 cell line was chosen for the knockdown study ([Figure 1B](#F0001){ref-type="fig"}). Two siRNAs targeting circ_0079586 were tested for decreasing circ_0079586 levels in LN229 cells, of which si-circ_0079586-1 showed the highest efficiency and was chosen for subsequent experiments ([Figure 2A](#F0002){ref-type="fig"}). Further, the U251 cell showed the lowest expression of circ_0079586 and was chosen for the overexpression study ([Figure 2B](#F0002){ref-type="fig"}). The analysis of the CCK-8 assay indicated that the cell viability was significantly reduced upon knockdown of circ_0079586 in LN229 cells, whereas, its ectopic expression increased cell growth in U251 cells ([Figure 2C](#F0002){ref-type="fig"}). Next, transfection of si-circ_0079586 increased the rate of cell apoptosis in LN229 cells, and its over-expression reduced apoptosis of U251 cells ([Figure 2D](#F0002){ref-type="fig"}). The knockdown of circ_0079586 suppressed the cell migration of LN229 cells, while migration increased with its over-expression in U251 cells ([Figure 2E](#F0002){ref-type="fig"}). Additionally, similar results were obtained with the cell invasion assay upon knockdown and over-expression of circ_0079586 ([Figure 2F](#F0002){ref-type="fig"}). Taken together, the above results show that circ_0079586 has important function in modulating the cell growth, apoptosis, cell migration and cell invasion phenotype of GM cells.Figure 2Circ_0079586 promotes progression of GM cells. (**A**) qRT-PCR analysis of circ_0079586 expression in LN229 cells. (**B**) Circ_0079586 expression after transfection in U251 cells analyzed by qRT-PCR. (**C**) Analysis of CCK-8 assays depicting cell viability in LN229 and U251 cells after transfection. (**D**) Flow cytometric analysis depicting cell apoptosis in LN229 and U251 cells after transfection. (**E**) Wound healing assay data analysis was performed to detect cell migration in LN229 and U251 cells after transfection. Scale bar=50μm. (**F**) Transwell assay was used to detect cell invasion in LN229 and U251 cells after transfection. \**p* \< 0.05, \*\**p* \< 0.01.

Circ_0079586 Regulates the Expression of *MDM4* by Sponging miR-183-5p {#S0003-S2003}
----------------------------------------------------------------------

As described earlier, the subcellular location of circRNA determines its specific functions.[@CIT0006] Our analysis of the subcellular fractions indicated that circ_0079586 was enriched in the cytoplasm of LN229 (79.5%) and U251 (78.6%) cells ([Figure 3A](#F0003){ref-type="fig"}). Based on this observation, we hypothesized that circ_0079586 may regulate the posttranscriptional activity in GM cells. We analyzed the circular RNA interactome that predicted 26 candidate miRNAs, while the circBANK database identified 70 miRNAs as possible candidates to bind circ_0079586. An overlap of these datasets identified three miRNAs (miR-127-5p, miR-183-5p and miR-433) to be common. We validated the expression of these miRNAs using qRT-PCR, which indicated only miR-183-5p to be negatively regulated by circ_0079586 in GM cells ([Figure 3B](#F0003){ref-type="fig"}). Further, our bioinformatics analysis predicted circ_0079586 to harbor conserved binding sites for miR-183-5p with a high score (312--318; 539--545, [Figure 3C](#F0003){ref-type="fig"}). Additionally, our analysis suggested an inverse expression of circ_0079586 and miR-183-5p ([Figure 3D](#F0003){ref-type="fig"}). Subsequently, luciferase reporter assay was carried out in the LN229 and U251 cells to confirm the bioinformatics prediction. The results indicated that overexpression of miR-183-5p significantly decreased the luciferase signal intensity in WT cells ([Figure 3E](#F0003){ref-type="fig"}). To understand the biological interactions of miR-183-5p in GM, the putative targets were searched using TargetScan7.2. As shown in [Figure 3C](#F0003){ref-type="fig"}, miR-183-5p also had complementary binding sites in the 3ʹUTR of *MDM4*. Moreover, the transcript levels of *MDM4* were decreased upon transfection of miR-183-5p mimics in LN229 and U251 cells than with miR-NC, whereas, the miR-183-5p inhibitor reversed the effect ([Figure 3F](#F0003){ref-type="fig"}). Next, the Western blot analysis indicated that the relative expression of MDM4 was significantly down-regulated in LN229 cells transfected with si-circ_0079586, whereas, inhibition of miR-183-5p or over-expression of *MDM4* rescued the expression of MDM4 ([Figure 3G](#F0003){ref-type="fig"}). Further, in U251 cells, either miR-183-5p mimics or si-*MDM4* partially decreased the expression of circ_0079586 ([Figure 3G](#F0003){ref-type="fig"}). Additionally, we identified a positive correlation between the expression of circ_0079586 and *MDM4* in the GM tissue samples ([Figure 3H](#F0003){ref-type="fig"}). Moreover, the luciferase reporter test indicated that the luciferase activity of *MDM4* 3ʹ-UTR WT was significantly reduced, but not *MDM4* 3ʹUTR MUT, in the LN229 and U251 cells transfected with miR-183-5p mimics ([Figure 3I](#F0003){ref-type="fig"}). Taken together, these results suggest circ_0079586 to regulate *MDM4* by sponging the activity of miR-183-5p.Figure 3Circ_0079586 sponges miR-183-5p activity to elevate expression of MDM4. (**A**) qRT-PCR detection of the percentage of circ_0079586, *GAPDH* and *U6* in the cytoplasm and nuclear fractions of LN229 and U251 cells. (**B**) Relative miRNA expression was detected in LN229 and U251 cells after transfection. (**C**) Schematic depicting the binding sites of miR-183-5p in circ_0079586/3ʹUTR of *MDM4*. (**D**) Correlation of expression of circ_0079586 and miR-183-5p in tissues from GM patients. (**E**) Luciferase reporter assay was conducted to evaluate the interaction between miR-183-5p and circ_0079586. (**F**) Relative *MDM4* expression was detected in LN229 and U251 cells after transfection by qRT-PCR assay. (**G**) Western blot analysis for detecting MDM4 expression in LN229 and U251 cells after transfection. (**H**) Correlation analysis of expression of circ_0079586 and *MDM4* in GM tissue samples. (**I**) Luciferase reporter assay was conducted to evaluate the interaction between 3ʹUTR of *MDM4* and miR-183-5p. \**p* \< 0.05, \*\**p* \< 0.01.

Circ_0079586 Increases GM Cell Oncogenesis by Regulating the miR-183-5p/*MDM4* Pathway {#S0003-S2004}
--------------------------------------------------------------------------------------

To elucidate the relationship between circ_0079586, miR-183-5p and *MDM4* in GM, si-circ_0079586 and miR-183-5p inhibitor were co-transfected into the LN229 cells. As shown in [Figure 4A](#F0004){ref-type="fig"}--[C](#F0004){ref-type="fig"}, silencing the expression of circ_0079586 inhibited cell proliferation and invasion, and boosted cell apoptosis, whereas inhibition of miR-183-5p or *MDM4* vector rescued these phenotype. On the contrary, the oncogenic properties induced by circ_0079586 vector were partly inhibited by miR-183-5p mimics or si-*MDM4* ([Figure 4A](#F0004){ref-type="fig"}--[C](#F0004){ref-type="fig"}).Figure 4The oncogenic activity of circ_0079586 is dependent on the miR-183-5p/*MDM4* signal axis. (**A**) Analysis of CCK-8 assay depicting cell viability after transfection in LN229 and U251 cells. (**B**) Analysis of the flow cytometric assay to evaluate cell apoptosis after transfection in LN229 and U251 cells. (**C**) Transwell assays were performed to evaluate cell invasion after transfection in LN229 and U251 cells. \**p* \< 0.05, \*\**p* \< 0.01.

Discussion {#S0004}
==========

CircRNAs have been reported to serve either as oncogenes or tumor suppressors during progression of several cancers, including GM.[@CIT0014] The circ_0079593 was found to be up-regulated, and its overexpression elevated cell proliferation and restrained cell apoptosis by targeting miR-182 and miR-433 in GM cells.[@CIT0015] Hsa_circ_0014359 was shown to facilitate GM progression via the PI3K signaling pathway by sponging miR-153.[@CIT0016] Further, Wang et al used circRNA microarrays to screen circRNAs differentially expressed in GM neoplasm and non-neoplasm tissues. Wang et al screened the differentially expressed circRNAs in GM tumor and non-tumor tissues using the circRNA microarray.[@CIT0013] From their list of up-regulated circRNAs, we chose circ_0079586 to investigate its role in GM. circ_0079586 is located on chr7: 23353140--23383472 and is back-spliced from the *IGF2BP3* gene to generate a 586bp transcript.

Here, we observed up-regulation of circ_0079586 in four cell lines and sixty cases of GM tissues. Moreover, the over-expression of circ_0079586 correlated with clinicopathological factors such as tumor size and advanced WHO grade tumors in GM patients. Furthermore, Kaplan--Meier survival analysis showed that the overall survival rate of GM patients with increased circ_0079586 expression was lower than that of patients with lower circ_0079586 levels. However, the multivariate analysis failed to demonstrate the independent prognostic role of circ_0079586, possibly due to the smaller sample size, and a larger patient cohort should allow making inference the Cox regression analysis. Next, our in vitro functional experiments indicated that circ_0079586 could promote cell growth, migration and invasion in GM cell lines. Additionally, the oncogenic functions of circ_0079586 can be partially attributed to the inhibition of cell apoptosis, together suggesting its role in occurrence and progression of GM.

Studies indicate that circRNAs play a part of competing endogenous RNAs (ceRNAs) for sponge miRNAs, thereby affecting the function of target mRNA expression.[@CIT0012]--[@CIT0016] Interestingly, we found circ_0079586 to be localized in the cytoplasm, and to act as a miR-sponge for miR-183-5p, thus supporting its potential role as a ceRNA. Several studies have shown that the expression level of miR-183-5p is low in many cancers.[@CIT0017]--[@CIT0019] Downstream targets of miR-183-5p, such as Erbin, PIK3CA, Ezrin, and so on, have been identified in various cancer types.[@CIT0017]--[@CIT0019] Consistent with these reports, our analysis identified low expression of miR-183-5p in GM tissues. Using TargetScan and luciferase reporter assay, we validated miR-183-5p to bind the 3ʹUTR of *MDM4* in GM cells. Further, we confirmed their association by silencing and over-expressing miR-183-5p that led to inversely related expression pattern of *MDM4* in these cells. MDM4 is known to inhibit the transcriptional activity of p53 by binding to the E3 ubiquitin ligase of MDM2 and promoting p53 ubiquitination and proteasomal degradation.[@CIT0020],[@CIT0021] Multiple studies have demonstrated *MDM4* to be regulated at the posttranscriptional level and play an oncogenic role in cancers of the lung (non-small cell lung cancer), the colon, and the pancreas.[@CIT0022]--[@CIT0024] Furthermore, *MDM4* has been shown to increase the hazard of GM susceptivity in the Han Chinese population.[@CIT0025] Additionally, the study by Xie et al identified *let-7* to bind *MDM4* and contribute to the DNA damage response in GM.[@CIT0026] Thus, these reports together with our analysis implicate *MDM4*, and its regulators and targets to be involved in tumor formation and progression in GM.

Conclusion {#S0005}
==========

In conclusion, our analysis demonstrates the circ_0079586/miR-183-5p/*MDM4* pathway to possibly regulate GM cell progression. Moreover, we anticipate this newer regulatory network to provide novel biomarkers for diagnosis and prognosis in patients with GM.
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[^1]: **Notes:** \**P* \< 0.05, \*\**P* \< 0.01.

[^2]: **Notes:** \**P* \< 0.05. HR, hazard ratio; 95% CI, 95% confidence interval.
